How to Formulate a GR + Myrosinase Capsule That Actually Generates Sulforaphane
A glucoraphanin myrosinase formulation sounds straightforward on paper: pair the precursor with the enzyme and let the conversion happen in the gut. In practice, most supplements labelled “with myrosinase” have never been tested for what they actually generate after the capsule is swallowed. The enzyme may have lost half its activity by month six. It may denature in stomach acid before reaching the GR it was supposed to convert. The enzyme source itself may push glucoraphanin toward an inactive nitrile instead of sulforaphane. Adding myrosinase to a label is easy. Making it work in a finished product is an engineering problem with at least eight variables.
This article is not an introduction to myrosinase — our GR vs SF decision guide covers the basics and the route-selection logic. This is a formulation manual. Eight steps, each with specific parameters, an industry benchmark and the mistakes that waste your development time.
For grade-by-grade GR and myrosinase specifications, see our broccoli seed extract product page.
Step 1
Choose Your Enzyme Source for a Glucoraphanin Myrosinase Formulation
Four commercially relevant myrosinase sources exist. They are not interchangeable. Their pH optima, thermal tolerances and side-reaction profiles differ enough that the wrong choice can reduce your sulforaphane yield to near zero — even with plenty of enzyme activity on the COA.
| Dimension | White mustard seed (S. alba) | Red cabbage | Horseradish root | Broccoli sprouts (freeze-dried) |
|---|---|---|---|---|
| pH optimum | 4.5–6.5 | ~8.0 | ~7.0 | 3.0–6.0 (literature varies) |
| Temperature optimum | ~60°C | 35–55°C range | ~45°C | 30–60°C |
| ESP content | Minimal or absent | Minimal or absent | Absent | Present — promotes nitrile |
| Human clinical data | Mastaloudis 2026 (n=16)[1] | No head-to-head human trial | No supplement human data | Avmacol (multiple clinical trials)[8] |
| EU allergen status | Yes — Annex II | No | No | No |
| Market use | Life Extension, SulfoMax, Designs for Health | PhytoVale ≥220 U/g | Patent references; rare in supplements | Avmacol, BroccoMax (Jarrow) |
Why pH optimum matters more than total activity
Gastric fluid sits at pH 1.2–3. The duodenum rises to pH 5–6. The jejunum reaches pH 6–7. The ileum can approach pH 7.5–8. A mustard-seed enzyme with a pH optimum of 4.5–6.5 starts working as soon as stomach contents enter the duodenum, even if some acid carry-over persists. A red-cabbage enzyme with a pH optimum near 8 reaches peak activity only in the distal ileum. This means the two enzyme sources have different “conversion windows” in the digestive tract — mustard acts earlier and faster, red cabbage acts later. Neither is universally better; the right choice depends on your capsule disintegration timing and whether you use acid protection.
High activity does not guarantee high SF yield
A 2019 study extracted myrosinase from several Brassica sources and measured both activity (U/g) and actual SF output when the enzyme was applied to exogenous glucoraphanin. Broccoli myrosinase had the highest measured activity (1.147 U/g dry mass) but produced no detectable sulforaphane from GR in the exogenous hydrolysis test. Chinese flowering cabbage myrosinase, at only 0.249 U/g, successfully converted GR to SF[9]. The probable explanation: broccoli enzyme co-extracted with epithiospecifier protein, which diverted the reaction toward sulforaphane nitrile. Activity measures how fast the enzyme chews through sinigrin in a lab assay. It does not measure how much SF comes out the other end when ESP is also present.
Transparency note
All published human bioavailability studies for GR + exogenous myrosinase used mustard-seed enzyme (Mastaloudis 2026, Fahey 2019). PhytoVale’s enzyme option is from red cabbage. Both sources share the low-ESP advantage, and red cabbage avoids the EU mustard-allergen declaration — a real labelling benefit for products sold in Europe. But no published trial compares their in-body conversion performance head to head. Formulators should verify SF generation with whichever source they select, using the protocol in Step 6.
Step 2
Set the GR–to–Enzyme Ratio
How much enzyme per milligram of GR? No published human trial has tested multiple ratios in the same study. The best available data comes from a 2025 in vitro digestion model and a clinical-trial protocol document.
Zhu 2025: the 4:1 benchmark
A dynamic gastric-digestion study tested broccoli seed extract (GR source) and mustard seed powder (myrosinase source) at a 4:1 weight ratio (BSE:MSP), delivered in capsules. Conversion efficiency in simulated small-intestinal conditions reached 72.1%. The same ratio delivered as free powder converted only 29.3% — a 2.5-fold difference driven entirely by capsule protection of the enzyme through the gastric phase[2]. This is the only published study to report a specific GR:Myr weight ratio alongside conversion efficiency in a digestion model.
Avmacol: an industry reference point
Clinical-trial protocol documents for Avmacol — the most clinically studied GR + myrosinase supplement — disclose the real formulation[8]: 125 mg broccoli seed powder + 50 mg freeze-dried broccoli sprout extract per tablet, delivering approximately 15–17 mg glucoraphanin with “enough myrosinase to fully hydrolyse the glucoraphanin contained in the tablet.” The manufacturer estimates 40–50% bioconversion to SF. That is roughly a 2.5:1 seed-powder-to-sprout-extract ratio, where the sprout extract is the myrosinase carrier.
Use 4:1 (GR extract : enzyme powder, w/w) as a starting configuration for any glucoraphanin myrosinase formulation bench trial. But the ratio is not the only variable — enzyme U/g, ascorbic acid, capsule type and storage conditions all modulate the outcome. The only reliable answer for your specific formulation comes from the conversion test in Step 6.
Do not scale by simple arithmetic
Doubling the enzyme proportion does not double the SF yield. Myrosinase follows Michaelis-Menten kinetics with substrate inhibition — at high substrate (sinigrin/GR) concentrations, excess substrate can actually reduce the reaction rate[10]. More enzyme at a fixed GR level shows diminishing returns. Run the ratio optimisation in your actual matrix, not on a spreadsheet.
Step 3
Add Ascorbic Acid as a Cofactor
Ascorbic acid is a known myrosinase cofactor that accelerates the hydrolysis reaction. This is not optional supplementation — it is a formulation parameter that changes conversion kinetics measurably.
In vitro data from patent literature: at 1 mmol/L ascorbic acid, 38°C, GR-to-SF conversion was nearly complete within 30 minutes. Without ascorbic acid, the same enzyme completed conversion but more slowly. Above 2 mmol/L, the response plateaued — additional ascorbic acid gave negligible further improvement[11].
The Zhu 2025 digestion model confirmed that ascorbic acid combined with mustard-seed myrosinase further enhanced conversion efficiency in simulated small-intestinal conditions and improved SF bioavailability across Caco-2 cell monolayers[2].
Industry-standard dose: 100 mg vitamin C per serving. Life Extension, Thorne and Avmacol all use this amount. It is not arbitrary — 100 mg of ascorbic acid in the volume of a dissolving capsule approximates 1–2 mmol/L, sitting in the optimal range from the in vitro data.
Preferred form: calcium ascorbate. The spray-dried myrosinase/ascorbate patent (US 10,925,934) specifically names calcium ascorbate for the spray-drying process — its buffering capacity is gentler on enzyme protein structure than free ascorbic acid at equivalent concentrations[11].
A data note from Mastaloudis 2026
Both arms of the Mastaloudis crossover trial — GR-only and GR + mustard myrosinase — included vitamin C. The 18.6% baseline in the GR-only arm was higher than the historical ~10% average from earlier studies without VC[1]. The enzyme drove most of the difference (18.6% → 39.8%), but the elevated baseline suggests VC also contributed. In a commercial formulation, including both enzyme and VC is the evidence-supported default.
Step 4
Keep GR and Enzyme Apart Until Activation
GR and myrosinase in the same powder with even trace moisture will react during storage. The enzyme hydrolyses GR, generates SF, and then SF degrades in the sealed package. The consumer opens the bottle months later to find less GR and less functional enzyme than the release-date COA promised.
This is the most overlooked engineering step in any glucoraphanin myrosinase formulation, and it explains a design choice visible in the market’s most-studied product: Avmacol uses freeze-dried broccoli sprouts as the myrosinase carrier. Freeze-drying drives water activity far below the threshold where myrosinase can act on GR in the dry state. The enzyme and its substrate coexist in the tablet, inert, until the consumer swallows it and digestive fluid provides the water that starts the reaction.
Strategies to prevent premature activation
| Strategy | How it works | Practical notes |
|---|---|---|
| Water-activity control | Keep Aw < 0.3 across all ingredients and finished product. No water = no reaction | Cheapest and most common approach. Requires dry blending, controlled-humidity fill and moisture-barrier packaging. Industry standard |
| Dual-chamber capsule | GR on one side, enzyme + VC on the other. Physical separation until capsule dissolves in the GI tract | Best theoretical isolation. Higher capsule cost and specialised filling equipment. Some contract manufacturers offer this |
| Bilayer tablet | GR layer pressed against enzyme layer. Layers mix only after tablet disintegrates | Proven in Avmacol’s tablet format. Requires bilayer press capability |
| Separate dosing | GR in capsule, enzyme in sachet. Consumer takes both together | Simplest manufacturing; worst consumer compliance. Two items per dose |
For most new products, water-activity control in a single capsule is the practical starting point. It works — Avmacol’s own shelf-life data supports the approach — and it does not require specialty equipment. The spray-dried myrosinase/ascorbate process described in patent US 10,925,934 was designed with exactly this problem in mind: the enzyme is locked into a dry ascorbate matrix that resists ambient moisture[11].
Test water activity of the blended fill at production and at 3, 6 and 12 months. If Aw creeps above 0.3 during storage, your packaging is not doing its job.
Step 5
Protect the Enzyme from Stomach Acid
The enzyme needs water and a pH above ~4 to work. The stomach provides plenty of water — at pH 1.2. If the capsule opens in the stomach, myrosinase denatures before GR reaches the small intestine. Three strategies exist, and the data is less straightforward than “enteric = better.”
| Strategy | Data | Caveat |
|---|---|---|
| Standard capsule | Nootropics Depot dissolution testing: myrosinase largely inactivated at pH 1.2[12]. Mastaloudis 2026 GR-only arm (with VC but no external enzyme): only 8% recovery in first 8 hours[1] | Cheapest option. Conversion depends almost entirely on surviving gut bacteria |
| Enteric / delayed-release | JHU PPI study: enteric-coated tablet ~36% conversion regardless of PPI use[3]. Zhu 2025 in vitro: capsule delivery 72.1% vs free powder 29.3%[2] | See Otago finding below |
| Pre-conversion in water | SulfoMax: 27 mg SF/serving by UPLC; stable through simulated gastric fluid[12] | Powder-only format; no capsule or tablet option; company data, not independent clinical trial |
The Otago counterpoint: enteric coating is not a guaranteed fix
A University of Otago study tested gastro-resistant polymer-coated capsules containing broccoli sprout powder. The enteric coating delayed ITC excretion — confirming the capsule survived the stomach. But total ITC metabolite recovery was significantly lower than from standard capsules. The researchers concluded the coating was too effective: the capsule broke down too slowly in the intestine, and the enzyme and substrate missed their optimal conversion window[13].
The lesson: enteric coating is a disintegration-time optimisation problem, not a binary yes/no. Too fast and the enzyme hits acid. Too slow and it never reaches GR in time. If you use enteric coating, test the actual disintegration profile in simulated intestinal fluid (pH 6.8, 37°C) and confirm SF generation at the time point where the capsule opens. A 30-minute delay may work; a 90-minute delay may not.
Step 6
Verify That Your Finished Product Actually Generates SF
Your enzyme supplier’s COA tells you the activity of the raw material. It does not tell you whether your finished capsule produces sulforaphane after the enzyme, GR, excipients, coating, storage conditions and fill moisture all interact.
Why U/g from a raw-material COA is not enough
The standard myrosinase activity unit: 1 U = amount of enzyme catalysing hydrolysis of 1 μmol sinigrin per minute under defined conditions. But those defined conditions vary between laboratories:
| Method | What it measures | Strength / limitation |
|---|---|---|
| UV spectrophotometry (227 nm) | Decrease in sinigrin absorbance | Fastest and most common. Does not distinguish whether sinigrin became SF or nitrile |
| Glucose oxidase coupled assay | Glucose released by myrosinase hydrolysis | More specific to myrosinase (sulfatase does not release glucose). Slightly slower |
| HPLC substrate depletion | Sinigrin disappearance by chromatographic separation | Most precise. Can simultaneously track sinigrin and products. Most expensive |
pH matters enormously: the same enzyme assayed at pH 6.5 and at pH 4.5 can return U/g values that differ by several-fold[4][5]. A “220 U/g” spec from one supplier and a “220 U/g” spec from another are not equivalent unless both used the same substrate concentration, buffer, pH, temperature and detection method.
The test you actually need: finished-product conversion capacity
Open a finished capsule. Suspend the contents in simulated intestinal fluid (phosphate buffer, pH 6.5–7.0, 37°C). Sample at 0, 15, 30, 60 and 120 minutes. Quantify both residual GR and newly formed SF by HPLC or LC-MS at each time point.
This gives you a conversion curve: how much SF is generated, how fast, and whether the reaction plateaus or the SF starts to degrade. Run it on release-date product and on aged product (see Step 7).
Analytical method trap
A 2026 study found that conventional high-temperature GC-MS sample injection caused over 60% sulforaphane degradation; an optimised protocol reduced losses to below 1%[14]. If your lab uses GC-MS for SF quantification, ask whether the method has been validated specifically for sulforaphane thermal stability during injection. A false-low SF reading makes a good product look like it failed — or makes a bad product look like it never had SF to begin with. HPLC and LC-MS avoid this problem.
Step 7
Protect Enzyme Activity Through Shelf Life
A capsule that generates 10 mg SF on the day it was filled may generate 3 mg SF when a consumer buys it fourteen months later. The difference is enzyme decay, and the primary driver is water.
Water activity is the first variable
A thesis-length study on broccoli myrosinase stability (Castelo-Branco, ISA Lisbon) measured thermal inactivation across freeze-dried broccoli samples with different moisture contents. The driest samples were substantially more thermostable and showed lower activation energies for degradation — meaning they were less sensitive to temperature fluctuations during shipping and warehousing[6]. This tracks with the broader enzyme-stability literature: at low Aw, protein mobility drops and denaturation slows.
Storage decay: some reference points
| System | Storage condition | Residual enzyme activity | Source |
|---|---|---|---|
| Grated horseradish root | 4°C, 2 weeks | ~10% | Italian university study[7] |
| Grated radish root | −20°C, 2 months | ~50% | Same study[7] |
| Purified cauliflower myrosinase | 4°C, solution | Stable for months | Cauliflower purification study[10] |
| Immobilised myrosinase on Con-A gel | 4°C, 20% glycerol | No significant loss, 7+ days | Fahey patent[15] |
These are lab-system numbers, not finished-product data. A dry capsule fill with Aw < 0.3 in moisture-barrier packaging will hold activity far longer than grated root at 4°C. But the principle holds: moisture accelerates enzyme death, cold slows it, and purified enzyme in a protective matrix outlasts crude plant material.
What to do in practice
- Dual-timepoint conversion testing: run the Step 6 protocol at release and at 12 months. If SF yield drops below 80% of release value, increase the enzyme overage in the next production run
- Accelerated stability: 40°C / 75% RH for 6 months predicts 24-month ambient performance. Request this from your enzyme supplier for the raw material; run it yourself on the finished capsule
- Packaging: aluminium foil inner bag with desiccant sachet outperforms HDPE bottle for moisture-sensitive enzyme blends
- Overage strategy: build 15–25% enzyme overage into the formula if your stability data shows measurable decay at 12 months. This is standard practice for enzyme-containing supplements
Step 8
Match the Dosage Form to the Enzyme
Everything above assumes a dry capsule or tablet — the default format for a glucoraphanin myrosinase formulation. If your product concept is a gummy, a drink or a chewable, some of these steps become impossible — and the GR + enzyme route may not be the right choice.
| Dosage form | GR + enzyme feasibility | Core challenge | Recommendation |
|---|---|---|---|
| Dry capsule (standard or enteric) | Best fit | Gastric acid protection (Step 5) | Default format for this route. All data in this article applies |
| Pressed tablet | Feasible with care | Granulation heat and moisture can reduce enzyme activity | Prefer direct compression over wet granulation. Test enzyme activity post-compression |
| Powder sachet | Feasible — new route | Consumer adds water; conversion happens in the glass | Buffer pH with potassium bicarbonate. Label “drink within 5 minutes”. Test SF in reconstituted product[12] |
| Gummy | Not feasible | Manufacturing at 80–90°C + Aw 0.55–0.70 destroys enzyme during production | Switch to preformed SF or GR-only route. See preformed SF options |
| Chewable tablet | Limited | Flavouring acids lower pH; higher moisture than dry capsule | Cold-press only. Must verify post-manufacture enzyme activity and SF generation |
| Ready-to-drink liquid | Not feasible | Enzyme and GR react continuously in liquid; SF degrades over shelf life | Instant-mix powder sachet works (see above). Pre-made liquid does not |
If your product concept is a gummy or a ready-to-drink liquid, the GR + myrosinase route is not viable. Go back to the route selection guide and evaluate preformed stabilised SF or GR-only as alternatives.
FAQ
Frequently Asked Questions
Does 220 U/g mean my capsule will produce a specific amount of sulforaphane?
No. U/g measures how fast the enzyme hydrolyses sinigrin under a defined set of lab conditions (pH, temperature, buffer). It does not predict how much SF will form in your capsule, which depends on the GR amount, ascorbic acid presence, capsule dissolution timing, pH environment and competing nitrile pathways. The only way to know is a finished-product conversion test (Step 6).
Is mustard-seed myrosinase better than red-cabbage myrosinase?
Mustard seed has stronger clinical evidence (Mastaloudis 2026 human trial) and a lower pH optimum (4.5–6.5), which means it starts working earlier in the duodenum. Red cabbage has no EU allergen declaration requirement and a pH optimum near 8, which suits distal small-intestine delivery. No published study compares them head to head in humans. Both lack ESP, which is the main reason to avoid using broccoli’s own endogenous enzyme.
Do I need enteric-coated capsules for a GR + myrosinase formula?
Enteric coating helps protect myrosinase from gastric acid, and the JHU PPI study showed ~36% conversion with enteric tablets. But a University of Otago study found that capsules coated too thickly broke down too slowly in the intestine, reducing total ITC recovery. Enteric coating is a disintegration-time optimisation problem, not a guaranteed upgrade. Test your specific coating in simulated gastric and intestinal fluid.
How much vitamin C should I add per serving?
100 mg of ascorbic acid or calcium ascorbate per serving, matching the dose used in Life Extension, Thorne and Avmacol formulations. In vitro data shows the myrosinase-accelerating effect plateaus above approximately 2 mmol/L, and 100 mg in a dissolving capsule approximates this concentration range. Calcium ascorbate is preferred for its gentler pH buffering.
Can I use the GR + myrosinase approach in a gummy?
No. Gummy manufacturing involves heating to 80–90°C and produces a matrix with water activity of 0.55–0.70. Myrosinase denatures under these conditions during production, before the product reaches the consumer. If your target format is a gummy, consider a preformed stabilised SF ingredient (PhytoVale SF 5% β-CD, ambient storage) or a GR-only approach.
References
References
Human bioavailability
[1] Mastaloudis A et al. (2026). Exogenous myrosinase from mustard seed increases bioavailability of sulforaphane from a glucoraphanin-rich broccoli seed extract in a randomized clinical study. Scientific Reports. n=16; GR-only 18.6% vs GR+Myr 39.8%. DOI: 10.1038/s41598-026-39389-4
[2] Zhu et al. (2025). Optimization of sulforaphane bioavailability from a glucoraphanin-rich broccoli seed extract in a model of dynamic gastric digestion and absorption by Caco-2 cell monolayers. Food & Function. BSE:MSP 4:1 in capsule = 72.1% conversion. DOI: 10.1039/D4FO04561K
[3] Fahey JW et al. (2019). Bioavailability of sulforaphane following ingestion of glucoraphanin-rich broccoli sprout and seed extracts with active myrosinase: a pilot study of the effects of proton pump inhibitor administration. Nutrients. Enteric-coated ~36%; uncoated with high acidity 25.7%. DOI: 10.3390/nu11071489
Enzyme characterisation
[4] Van Eylen D et al. (2008). Behavior of mustard seed (Sinapis alba L.) myrosinase during temperature/pressure treatments: a case study on enzyme activity and stability. J Food Eng. pH optimum 6.5; temperature optimum 60°C at atmospheric pressure; ascorbic acid and MgCl₂ enhance activity. DOI: 10.1016/j.jfoodeng.2008.02.003
[5] Verkerk R, Dekker M. (2004). Glucosinolates and myrosinase activity in red cabbage (Brassica oleracea L. var. capitata f. rubra DC.) after various microwave treatments. J Agric Food Chem. Red cabbage myrosinase retained substantial activity at low/intermediate microwave power; complete inactivation at 900 W/4.8 min. DOI: 10.1021/jf030694o
Stability
[6] Castelo-Branco JD. (2010). Myrosinase stability in broccoli (Brassica oleracea var. italica): influence of temperature and water activity. MSc thesis, ISA Lisbon. Driest freeze-dried samples showed highest thermal stability and lowest activation energies for degradation.
[7] Ferruzza S et al. Stability of myrosinase activity and glucosinolate content in horseradish and radish during storage. Univ. Basilicata. Grated horseradish at 4°C: 10% activity at 2 weeks; −20°C: 50% at 2 months.
Clinical formulation reference
[8] Nutramax Laboratories / JHU. Avmacol clinical trial protocols (NCT02909959, NCT02677051, NCT03399656). Formulation: 125 mg broccoli seed powder + 50 mg freeze-dried sprout extract; ~15–17 mg GR/tablet; estimated 40–50% bioconversion. ClinicalTrials.gov
Enzyme source and ESP
[9] Pongmalai P et al. (2019). Enhanced production of sulforaphane by exogenous glucoraphanin hydrolysis catalyzed by myrosinase extracted from Chinese flowering cabbage. Sci Rep. Broccoli myrosinase: highest activity (1.147 U/g) but no SF from exogenous GR; Chinese flowering cabbage (0.249 U/g) produced SF. DOI: 10.1038/s41598-019-43441-7
[10] Mahn A et al. (2014). Purification and characterization of broccoli (Brassica oleracea var. italica) myrosinase. J Agric Food Chem. Km = 0.086 mM, substrate inhibition Ki = 0.368 mM; stable at 4°C for months. DOI: 10.1021/jf405109e
Manufacturing technology
[11] Sullivan RC. (2021). US Patent 10,925,934. Spray dried myrosinase and use to produce isothiocyanates. Spray-dried myrosinase/calcium ascorbate mixture; improved stability and activity; sources include broccoli seed and daikon. Google Patents
[12] Nootropics Depot. (2026). SulfoMax launch. Press release, 8 Sep 2026. Dissolution testing: myrosinase inactivated in simulated gastric fluid; pre-converted SF stable at pH 1.2. Company data. PR Newswire
Enteric coating
[13] University of Otago. Bioavailability and biological effects of isothiocyanates from broccoli sprout powder. Doctoral thesis. Enteric-coated capsules delayed ITC excretion but reduced total recovery; capsule breakdown was too slow. OUR Archive
Analytical
[14] Melini V et al. (2026). Sulforaphane determination by GC-MS analysis: mitigation of thermal degradation. Molecules. >60% SF degradation from high-temperature injection; optimised to <1%. DOI: 10.3390/molecules31152598
[15] Fahey JW et al. (2014). US Patent 8,927,007. Formulations for treatment with glucosinolates. Immobilised myrosinase on Con-A gel; stable 7+ days at 4°C in glycerol. Google Patents
Reviewed by
Prof. Bingji MaScientific Advisor, PhytoVale · Professor & Medicinal Plant Science Expert. Research focus: Chinese medicinal materials, phytochemistry, natural products and medicinal plant quality.
Written by
FloraProduct content and editorial specialist, focused on botanical ingredient specifications, sourcing information and B2B technical content.
Disclaimer: PhytoVale supplies the glucoraphanin grades and red-cabbage myrosinase preparation discussed in this article. This content is provided for ingredient evaluation, formulation reference and B2B purchasing decisions. It does not constitute medical advice or regulatory guidance. Formulation parameters and conversion data are drawn from published studies and patent literature as of October 2026; conditions and results may differ in your specific product. Finished-product manufacturers are responsible for their own formulation development, testing, labelling and regulatory compliance. © 2026 PhytoVale.
Find the Right Glucoraphanin or Sulforaphane Grade
Formulating with glucoraphanin, myrosinase or preformed sulforaphane? PhytoVale offers GR 13%, stabilised SF 5% and concentrated SF 10% grades, along with red-cabbage myrosinase. Tell us your target compound, dosage form and destination market. We can provide grade-specific specifications, COAs and sample options for your formulation evaluation.
Specify your target GR or SF content, dosage form and estimated order quantity.
